Stockreport

Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans – And What's Next [Yahoo! Finance]

CLINUVEL PHARMS LTD S/ADR  (CLVLY) 
NASDAQ:AMEX Investor Relations: clinuvel.com/investors
PDF Clinuvel Pharmaceuticals recently reported full-year revenue of A$105.3 million and net income of A$36.17 million, declared its eighth consecutive annual dividend of A$0 [Read more]